Alamar Biosciences

Alamar Biosciences is a private, precision proteomics company building a vertically integrated platform (ARGO instrument, NULISA consumables, software) for ultra-sensitive, multiplex protein detection. The company is targeting the high-growth biomarker discovery and early disease detection market, with a strong initial focus on neurological conditions like Alzheimer's and Parkinson's disease. Backed by notable investors and led by a seasoned team with experience in proteomics, diagnostics, and scaling biotech companies, Alamar is transitioning from platform development to commercial launch of its research-use-only products.

NULISA (NUcleic-Linked Immuno-Sandwich Assay) platform, an ultra-sensitive proteomics technology that uses oligonucleotide-tagged antibodies and cDNA qPCR for signal amplification. It is integrated with the automated ARGO instrument for end-to-end sample processing and analysis.

Alamar competes in the high-sensitivity proteomics space against companies like Olink (now part of Thermo Fisher), Quanterix (SIMOA technology), and SomaLogic. Its key differentiators are the claimed attomolar sensitivity of its NULISA technology, the fully automated ARGO workflow, and its focused panels for neurodegenerative diseases. Success depends on proving superior performance and workflow advantages to gain market share.